<DOC>
	<DOCNO>NCT02488525</DOCNO>
	<brief_summary>Main objective study demonstrate prophylactic treatment VWF factor concentrate implantation continuous-flow leave ventricular assist device ( CF-LVAD ) reduce frequency clinically significant bleeding within 3 month implantation comparison usual care . Adult patient functional defect VWF measure implantation continuous LVAD randomly assign prophylactic treatment .</brief_summary>
	<brief_title>Prevention Hemorrhage After Implantation Mechanical Circulatory Support</brief_title>
	<detailed_description>This time point choose bleed event maximal within first 3 month implantation . - Adult patient &gt; 18 year need CF-LVAD due advance heart failure . - Functional To determine potential indication Wilfactin® field CF-LVAD avoid widespread use establish evidence-based recommendation To improve knowledge role VWF concentrate bleed angiogenesis CF-LVAD implantation provide result mechanism involve angiogenesis hemostasis .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<criteria>Adult patient &gt; 18 year need CFLVAD due advance heart failure . Functional defect VWF measure day 2 day 4 implantation ( either PFAADP closure time &gt; 250 sec VWF : Act/VWF : Ag &lt; 0.7 ) Informed consent patient support person case disability baseline ( patient intubate ventilate ) Treatment Wilfactin® within last seven day Previous adverse reaction Wilfactin® Absence functional defect VWF measure day 2 day 4 implantation ( either PFAADP closure time &gt; 250 sec VWF : Act/VWF : Ag &lt; 0.7 ) Patient know thrombophilia Patient know severe bleed disorder Patient refusal environment Minor patient Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Acquired Von Willebrand</keyword>
	<keyword>Gastro-intestinal bleeding</keyword>
	<keyword>LVAD</keyword>
</DOC>